Organizer

Oct. 12 (Thu.) ,2017 11:45-13:45

Annex Hall
F203/F204

Simultaneous Interpretation

【O-7】 Gene Therapy Update
― Commercialization of CAR-T and TCR-T gene therapy; Progress and Challenges ―

In recent years, gene-modified T (CAR-T and TCR-T) cell therapy has rapidly developed as very efficient cancer gene therapy, and movement towards commercialization is accelerating. In this session, we will invite distinguished speakers from companies and academia in US, UK, Australia and Japan who are actively engaged in the development of gene-modified T cell therapy, to overview up-to-date status of this gene therapy and to discuss challenges toward its commercialization.

Coordinator

Ozawa Keiya

Director, IMSUT Hospital Director, Center for Gene & Cell Therapy (CGCT) Professor, Division of Genetic Therapeutics, Advanced Clinical Research Center , The Institute of Medical Science, The University of Tokyo

Introduction: Trend of R&D of CAR-T gene therapy

Ozawa Keiya

Director, IMSUT Hospital Director, Center for Gene & Cell Therapy (CGCT) Professor, Division of Genetic Therapeutics, Advanced Clinical Research Center , The Institute of Medical Science, The University of Tokyo

Focused On The Cure

Zachary J Roberts

Senior Director, Clinical Development, Kite Pharma

NextGen Manufacturing Solutions for ATMP’s

David James

CEO, Scinogy

Clinical Development CD19 CAR and TCR gene therapy in Japan

Masanobu Kimura

PRESIDENT of GENE MEDICINE BUSINESS UNIT, TAKARA BIO

Optimizing Viral Vectors for T-Cell Immunotherapies

Paul Brooks

Chief Commercial Officer,, Oxford Genetics

Close Window